JPMorgan Chase & Co. Boosts Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET)

JPMorgan Chase & Co. grew its stake in shares of Adicet Bio, Inc. (NASDAQ:ACET) by 10,321.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 80,353 shares of the company’s stock after purchasing an additional 79,582 shares during the period. JPMorgan Chase & Co. owned approximately 0.10% of Adicet Bio worth $116,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ACET. Cubist Systematic Strategies LLC lifted its holdings in shares of Adicet Bio by 790.1% in the second quarter. Cubist Systematic Strategies LLC now owns 409,049 shares of the company’s stock valued at $495,000 after purchasing an additional 363,095 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Adicet Bio by 2,728.8% in the second quarter. Squarepoint Ops LLC now owns 362,230 shares of the company’s stock valued at $438,000 after acquiring an additional 349,425 shares in the last quarter. RBF Capital LLC boosted its stake in shares of Adicet Bio by 62.5% during the third quarter. RBF Capital LLC now owns 601,135 shares of the company’s stock valued at $866,000 after acquiring an additional 231,135 shares during the last quarter. AQR Capital Management LLC raised its stake in Adicet Bio by 478.3% in the 2nd quarter. AQR Capital Management LLC now owns 136,765 shares of the company’s stock valued at $165,000 after purchasing an additional 113,115 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Adicet Bio by 14.5% in the 3rd quarter. Geode Capital Management LLC now owns 768,566 shares of the company’s stock valued at $1,107,000 after purchasing an additional 97,567 shares in the last quarter. Hedge funds and other institutional investors own 83.89% of the company’s stock.

Adicet Bio Stock Down 0.6 %

Shares of NASDAQ ACET opened at $0.89 on Monday. The stock has a market capitalization of $72.92 million, a PE ratio of -0.52 and a beta of 1.87. The firm has a fifty day moving average of $0.96 and a 200-day moving average of $1.24. Adicet Bio, Inc. has a 52-week low of $0.81 and a 52-week high of $3.62.

Adicet Bio (NASDAQ:ACET) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, hitting analysts’ consensus estimates of ($0.34). Equities research analysts expect that Adicet Bio, Inc. will post -1.39 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ACET has been the subject of a number of recent research reports. Wedbush reiterated an “outperform” rating and set a $5.00 price target on shares of Adicet Bio in a report on Thursday, November 7th. HC Wainwright reiterated a “neutral” rating on shares of Adicet Bio in a research note on Thursday, December 19th. Finally, StockNews.com lowered Adicet Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Adicet Bio has a consensus rating of “Hold” and a consensus target price of $7.50.

Adicet Bio Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.